Acoziborole ( DrugBank: Acoziborole )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 2 |
65. Primary immunodeficiency
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05256017 (ClinicalTrials.gov) | December 30, 2021 | 17/1/2022 | Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects | Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Non-parasitologically Confirmed Subjects: a Multicentre Randomised Double-blind Placebo-controlled Study | Trypanosomiasis, African;Trypanosoma Brucei Gambiense; Infection;Sleeping Sickness | Drug: Acoziborole;Drug: Placebo | Drugs for Neglected Diseases | NULL | Recruiting | 15 Years | N/A | All | 1200 | Phase 2/Phase 3 | Congo, The Democratic Republic of the;Guinea |
| 2 | NCT03087955 (ClinicalTrials.gov) | October 11, 2016 | 7/3/2017 | Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense | Efficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study | Trypanosomiasis, African;Gambiense Trypanosomiasis;Sleeping Sickness | Drug: Acoziborole (SCYX-7158) | Drugs for Neglected Diseases | NULL | Completed | 15 Years | N/A | All | 260 | Phase 2/Phase 3 | Congo, The Democratic Republic of the;Guinea |